Relay Therapeutics (RLAY) Change in Accured Expenses (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Change in Accured Expenses data on file, last reported at $3.7 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $3.7 million, up 1290.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (down 74.25% YoY), and the FY2025 annual result was -$1.5 million, down 114.87% from the prior year.
• Change in Accured Expenses rose to $3.7 million in Q1 2026 per RLAY's latest filing, from -$615000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $17.9 million in Q3 2022 and troughed at -$19.5 million in Q3 2023.
• A 5-year average of $798411.8 and a median of $3.1 million in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2026: Change in Accured Expenses plunged 310.53% in 2022, then soared 1290.26% in 2026.
• A 5-year view of Change in Accured Expenses shows it stood at -$16.7 million in 2022, then soared by 135.01% to $5.8 million in 2023, then soared by 73.31% to $10.1 million in 2024, then sank by 106.08% to -$615000.0 in 2025, then soared by 696.1% to $3.7 million in 2026.
• Business Quant data shows RLAY's Change in Accured Expenses at $3.7 million in Q1 2026, -$615000.0 in Q4 2025, and $3.5 million in Q3 2025.